Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) will participate in a fireside chat at Morgan Stanley's 18th Annual Global Healthcare Conference at 3:45 p.m. ET on September 14, 2020. The clinical-stage biotechnology company focuses on treatments for non-alcoholic steatohepatitis (NASH) and other metabolic disorders. A live webcast will be available through their investor relations section, with an archived replay following the event. Akero's lead product, AKR-001, is currently in a Phase 2a clinical trial aimed at reversing the NASH epidemic.

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Morgan Stanley's 18^th Annual Global Healthcare Conference at 3:45 p.m. ET on Monday, September 14, 2020.

A live webcast of the presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA.  For more information, please visit www.akerotx.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-morgan-stanleys-18th-annual-global-healthcare-conference-301126806.html

SOURCE Akero Therapeutics, Inc.

FAQ

When is Akero Therapeutics participating in the Morgan Stanley Global Healthcare Conference?

Akero Therapeutics will participate in the conference on September 14, 2020, at 3:45 p.m. ET.

What is the focus of Akero Therapeutics?

Akero Therapeutics focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders.

How can I watch the Akero Therapeutics presentation?

You can watch the live webcast of Akero's presentation on their investor relations website.

What is AKR-001?

AKR-001 is Akero Therapeutics' lead product candidate currently being evaluated in a Phase 2a clinical trial.

Where is Akero Therapeutics headquartered?

Akero Therapeutics is headquartered in South San Francisco, California.